Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
Mark Ayers(Merck & Co., Inc., Rahway, NJ, USA (United States)), Terri McClanahan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Veena Shankaran(University of Washington), Erin Murphy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Nebozhyn(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrey Loboda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Andrew Albright(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antoni Ribas(University of California, Los Angeles), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), T. Seiwert(University of Chicago), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan D. Cheng(Princeton University), Jennifer H. Yearley(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 41
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k